FDA pushes trial transparency and shortens drug evidence bar
The FDA has asked roughly 2,200 sponsors and researchers to post certain clinical‑trial results to ClinicalTrials.gov as part of a transparency push. (biospace.com) Separately, reporting says the agency is moving toward accepting one adequate, well‑controlled trial in more cases rather than two, changing the evidentiary expectation for approvals. (pharmexec.com) (rttnews.com)
The Food and Drug Administration is pressing drugmakers to disclose missing trial results while signaling it may accept less preapproval trial evidence in more cases. (fda.gov 1) (fda.gov 2) On April 13, 2026, the agency said it had contacted more than 2,200 companies and researchers linked to more than 3,000 studies that appear to be missing required results on ClinicalTrials.gov. The Food and Drug Administration said those messages went out on March 30. (fda.gov) ClinicalTrials.gov is the federal database where sponsors must register many trials and later post summary results, including negative findings. Federal rules generally require results for applicable clinical trials within one year of the study’s primary completion date, unless an extension or delay applies. (clinicaltrials.gov 1) (clinicaltrials.gov 2) The Food and Drug Administration said companies often fail to post unfavorable outcomes, leaving gaps that can skew the public record toward success. In the same announcement, Commissioner Marty Makary said clinicians, patients, and researchers are left without information they need. (fda.gov) (content.govdelivery.com) At the same time, the agency’s evidence standard for approvals has been moving toward more use of one pivotal study plus supporting proof, instead of expecting two standalone positive trials in every case. The Food and Drug Administration’s 2023 draft guidance says one adequate, well-controlled investigation and confirmatory evidence can establish effectiveness in some settings. (fda.gov 1) (fda.gov 2) That approach is not entirely new. Food and Drug Administration materials say the law has long required “substantial evidence” of effectiveness, and agency guidance dating back to 1998 described circumstances where one trial, backed by other evidence, could be enough. (fda.gov) (fda.gov) The current shift is about how broadly that flexibility gets used. The 2019 and 2023 guidance documents describe one-trial pathways for new indications, rare diseases, and other situations where confirmatory evidence can come from related trials, dose-response data, or other clinical and scientific support. (fda.gov) (fda.gov) Drugmakers have argued for years that two large trials are not always practical, especially in small patient populations. Critics of lighter evidence standards have warned that fewer preapproval trials can leave more uncertainty about benefits and risks at the time a drug reaches the market. (fda.gov) (fda.gov) The two developments pull on different parts of the same system. If the Food and Drug Administration allows more approvals to rest on one main study, the public database becomes a more important backstop for seeing failed trials, delayed follow-up, and evidence that never made it into journal articles. (fda.gov) (clinicaltrials.gov) The agency said the March notices were a reminder, not a final enforcement action, but the law allows pre-notices, notices of noncompliance, and civil money penalties for missing submissions. The next test is whether thousands of overdue records actually get posted. (fda.gov) (clinicaltrials.gov)
